ஜர்னல் ஆஃப் கிளினிக்கல் & எக்ஸ்பெரிமென்டல் டெர்மட்டாலஜி ரிசர்ச்
திறந்த அணுகல்

சுருக்கம்

Erythema Nodosum-like Panniculitis Associated with the Use of Vemurafenib

Jorge Magdaleno Tapial, Cristian Valenzuela Oñate, Álvaro Martínez-Doménech, Daniela Subiabre Ferrer, Gemma Pérez Pastor, Pablo Hernández Bel and Víctor Alegre de Miquel

Melanoma a type of skin cancer derived from melanocytes which represents around 4% of all skin cancers recorded till date, but is responsible for 80% deaths due to skin tumors. The development of new targeted therapies directed specifically against malignant cells has brought hope to the treatment of melanoma patients. The first drugs developed against specific molecules were BRAF inhibitors, designed for the treatment of metastatic melanoma. These drugs have been demonstrated to improve both overall and disease-free survival in these patients. At the same time, a wide range of adverse events (AEs) have emerged from their use. Some of them are quite frequent and are observed regularly in everyday practice on the other hand, there are rare AEs that require an early diagnosis for adequate treatment so knowledge of their existence is crucial for timely recognition and patient management. We here have presented a case of erythema nodosum-like septal panniculitis in a patient receiving therapy with vemurafenib and cobimetinib.